SCHEMBL2587924

SCHEMBL2587924

COc1ccc(-c2ccc3c(c2)CNC3=O)c(OCC2(C(=O)OC3CCCC3)CC2)c1OC

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 8/20 0.39
GSK3B P49841 2/20 0.38
POLQ O75417 1/20 0.35
MAPT P10636 1/20 0.35
HTT P42858 1/20 0.35
TDP2 O95551 1/20 0.35
MAPKAPK2 P49137 1/20 0.35
TP53 P04637 1/20 0.34
PDE4A P27815 5/20 0.34
PDE4B Q07343 3/20 0.34
PDE4C Q08493 3/20 0.34
DAPK3 O43293 1/20 0.34
NTRK1 P04629 1/20 0.34
PIM1 P11309 1/20 0.34
FLT3 P36888 1/20 0.34
ROCK1 Q13464 1/20 0.34
CLK4 Q9HAZ1 1/20 0.34
PRKCI P41743 1/20 0.33
GPR119 Q8TDV5 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2593241 0.99 PDE4D (0.40) PDE4DGSK3BPOLQMAPTHTT
SCHEMBL2588185 0.99 PDE4D (0.40) PDE4DGSK3BPOLQMAPTHTT
SCHEMBL2584298 0.98 PDE4D (0.39) PDE4DGSK3BPOLQMAPTHTT
SCHEMBL2591320 0.97 PDE4D (0.39) PDE4DGSK3BPOLQMAPTHTT
SCHEMBL2592794 0.97 PDE4D (0.39) PDE4DGSK3BPOLQMAPTHTT
SCHEMBL2591719 0.97 PDE4D (0.39) PDE4DGSK3BPOLQMAPTHTT
SCHEMBL2584258 0.96 PDE4D (0.39) PDE4DGSK3BPOLQMAPTHTT
SCHEMBL2589278 0.93 PDE4D (0.41) PDE4DGSK3BPOLQTDP2MAPKAPK2
SCHEMBL2589503 0.92 PDE4D (0.40) PDE4DGSK3BPOLQTDP2MAPKAPK2
SCHEMBL2591397 0.91 POLQ (0.40) PDE4DGSK3BPOLQTDP2MAPKAPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2563770-B1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2016-03-23 EP disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed
EP-2563770-A1 BIARYL PHOSPHODIESTERASE INHIBITORS Leo Pharma A/S (DK) 2013-03-06 EP disclosed
WO-2011134468-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2011-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS PDE3B, PDE3A, PDE4A PDE4D 10/4885GSK3B 350/4885POLQ 1717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.